Search
Home
Latest
News
North America
Europe
Asia
Middle East
Global
Fortune 500
Fortune 500 U.S.
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Finance
Economy
Banking
Personal Finance
Investing
Real Estate
Energy
Crypto
Tech
Big Tech
Startups & Venture
AI
Innovation
Cybersecurity
Leadership
Future Of Work
Success
C-Suite
Workplace Culture
CEO Initiative
Lifestyle
Arts & Entertainment
Health
Travel & Leisure
Education
Rankings
Great Place To Work
Analytics
Multimedia
Live Media
Magazine
Newsletters
Press Releases
Video
Podcasts
Home
Latest
Latest
News
North America
Europe
Asia
Middle East
Global
Fortune 500
Fortune 500
Fortune 500 U.S.
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Finance
Finance
Economy
Banking
Personal Finance
Investing
Real Estate
Energy
Crypto
Tech
Tech
Big Tech
Startups & Venture
AI
Innovation
Cybersecurity
Leadership
Leadership
Future Of Work
Success
C-Suite
Workplace Culture
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Health
Travel & Leisure
Education
Rankings
Rankings
Great Place To Work
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Press Releases
Video
Podcasts
home
home
Gilead
Gilead
Health
U.S. approves twice-a-year shot to prevent HIV but cuts to public health and foreign aid cloud its prospects
By
Lauran Neergaard
and
The Associated Press
June 19, 2025
Health
A twice-yearly shot of this drug could help end AIDS — ‘it’s unprecedented’
By
Maria Cheng
,
María Verza
and
The Associated Press
December 2, 2024
Conferences
Gilead’s remdesivir is now used to treat half of hospitalized COVID patients
By
Sy Mukherjee
April 28, 2021
Finance
AstraZeneca’s stock is soaring on COVID, but the pandemic has dented its growth
By
Jeremy Kahn
November 6, 2020
Newsletters
Gilead just got the first FDA coronavirus treatment approval, but there are still problems
By
Sy Mukherjee
October 22, 2020
Health
Gilead says remdesivir slashes coronavirus deaths. But it’s complicated
By
Sy Mukherjee
July 10, 2020
Newsletters
Coronavirus exposes the trouble of scientific unknowns
By
Sy Mukherjee
July 10, 2020
Health
COVID treatment remdesivir will cost $520 per vial. But it may not be how much you pay
By
Sy Mukherjee
June 29, 2020
Health
Gilead to charge thousands for coronavirus treatment drug that critics say should cost $1
By
Robert Langreth
and
Bloomberg
June 29, 2020
Health
Gilead’s next COVID-19 treatment advancement could keep patients out of hospitals
By
Sy Mukherjee
June 22, 2020
Health
Rumors swirl about an AstraZeneca and Gilead megadeal—but it doesn’t make sense
By
Sy Mukherjee
June 8, 2020
Magazine
Will COVID-19 change how Big Pharma does clinical trials?
By
Erika Fry
May 15, 2020
Health
Antibody testing will be key—once we understand what the results mean
By
Sy Mukherjee
May 12, 2020
Newsletters
Gilead’s moral (and financial) COVID-19 conundrum
By
Sy Mukherjee
May 7, 2020
Health
Remdesivir is the first coronavirus treatment. So why is Gilead’s stock plunging?
By
Sy Mukherjee
May 1, 2020
Most Popular
Economy
The $38 trillion national debt is to blame for over $1 trillion in annual interest payments from here on out, CRFB says
By
Nick Lichtenberg
AI
'Robots are going to be amongst us': Qualcomm exec says buckle up for the next 5 years. Your car is going to be the...
By
Nino Paoli
C-Suite
Red Lobster CEO Damola Adamolekun says the key to being a better leader is being a better person: ‘Leadership is...
By
Sydney Lake